Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
Neha J. Pagidipati, Adam J. Nelson, Lisa A. Kaltenbach, et al.
JAMA (2023) Vol. 329, Iss. 15, pp. 1261-1261
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 193
Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease
Miguel Vazquez, Gretchen D. Oliver, Ruben Amarasingham, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1196-1206
Closed Access | Times Cited: 8
Electronic Health Record Population Health Management for Chronic Kidney Disease Care
Manisha Jhamb, Melanie R. Weltman, Susan M. Devaraj, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 7, pp. 737-737
Open Access | Times Cited: 8
Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial
Alexander Blood, Lee‐Shing Chang, Shahzad Hassan, et al.
Circulation (2024) Vol. 149, Iss. 23, pp. 1802-1811
Closed Access | Times Cited: 7
Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
David Kerr, Jigar Rajpura, Tarlan Namvar
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 411-424
Open Access | Times Cited: 6
Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies
Alexander Blood, Lee‐Shing Chang, Caitlin Colling, et al.
American Heart Journal (2025) Vol. 282, pp. 114-124
Closed Access
Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study
Rozalina G. McCoy, Jonathan L. Vandergrift, Bradley M. Gray
Diabetes Research and Clinical Practice (2025) Vol. 221, pp. 112039-112039
Open Access
Target Achievements of Low-Density Lipoprotein Cholesterol, Blood Pressure, and Glucose in Patients with Diabetes after Acute Coronary Syndrome: Findings from the Chinese Cardiovascular Association Database – iHeart Project
Jing Yang, Rui Zhang, Bing Han, et al.
Global Heart (2025) Vol. 20, Iss. 1, pp. 14-14
Open Access
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
Nancy Haff, Daniel M. Horn, Gauri Bhatkhande, et al.
American Heart Journal (2025)
Closed Access
Reminders EMbedded IN PCI Reports to Optimize Discharge Diabetes Mellitus Care (REMIND-DM): Rationale, Design, and Baseline Characteristics
Safia Chatur, Milan Seth, Mary Casey, et al.
American Heart Journal (2025)
Closed Access
Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience
Sium Wolde Sellasie, Chiara Pecchioli, K. Cersosimo, et al.
Acta Diabetologica (2025)
Open Access
Effect of a Population Health Management Intervention on Medication Therapy Problems in People With Chronic Kidney Disease: Post-hoc Analysis of the K-CHAMP Cluster Randomized Trial
Melanie R. Weltman, Zhuoheng Han, Linda-Marie U. Lavenburg, et al.
Kidney Medicine (2025), pp. 100995-100995
Open Access
Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data
Brendon L. Neuen, Min Jun, James Wick, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 43, pp. 100988-100988
Open Access | Times Cited: 12
Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank
Konstantin A. Krychtiuk, Tomas Andersson, Ulrike Bodesheim, et al.
American Heart Journal (2024) Vol. 270, pp. 23-43
Closed Access | Times Cited: 4
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
Daniel Edmonston, Elizabeth Lydon, Hillary Mulder, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2418808-e2418808
Open Access | Times Cited: 4
Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk
Alexander Blood, Lee‐Shing Chang, Caitlin Colling, et al.
Primary care diabetes (2024) Vol. 18, Iss. 2, pp. 202-209
Open Access | Times Cited: 3
Exploring novel lead scaffolds for SGLT2 inhibitors: Insights from machine learning and molecular dynamics simulations
Yuandong Yu, Yuting Xia, Guizhao Liang
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130375-130375
Closed Access | Times Cited: 3
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial
Manasi Tannu, Lisa A. Kaltenbach, Neha J. Pagidipati, et al.
Circulation (2024) Vol. 150, Iss. 3, pp. 180-189
Closed Access | Times Cited: 3
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Multidisciplinary proactive e-consults to improve guideline-directed medical therapies for patients with diabetes and chronic kidney disease: an implementation study
Sharon Rikin, Laurie J. Bauman, Ivelina Arnaoudova, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 3, pp. e004155-e004155
Open Access | Times Cited: 2
The Continuing Scourge of Atherosclerotic Cardiovascular Disease: Importance of Multidisciplinary and Innovative Person-Centred Approaches
Alice Cheng, Morgan B. Krauter, Kerri‐Anne Mullen, et al.
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 8, pp. S43-S52
Open Access | Times Cited: 2
Addressing Cardiovascular Risk in Diabetes: It’s More Than the Sugar
Bige Özkan, Chiadi E Ndumele
Circulation (2023) Vol. 147, Iss. 25, pp. 1887-1890
Open Access | Times Cited: 7
A system approach to improving guideline-directed therapy for cardio-renal-metabolic conditions: The “beyond diabetes” initiative
Benjamin J. Hirsh, Jamie S. Hirsch, Hosam Hmoud, et al.
American Journal of Preventive Cardiology (2023) Vol. 16, pp. 100608-100608
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top